BioMarin Welcomes Robert Plenge, M.D., Ph.D., to Its Board of Directors as New Chief Research Officer

BioMarin Welcomes a New Visionary to its Board

BioMarin Pharmaceutical Inc. announced on September 14, 2026, the appointment of Dr. Robert Plenge, a well-respected leader in pharmaceutical research, to its Board of Directors. This strategic move is viewed as a significant enhancement to BioMarin's mission of developing innovative therapies for patients with rare genetic conditions.

Dr. Plenge, who currently serves as the Chief Research Officer and Executive Vice President at Bristol Myers Squibb, is set to bring a wealth of expertise to his new role. With his leadership at nine global research sites, Dr. Plenge has been at the forefront of pivotal scientific advancements. He joined Bristol Myers Squibb following their acquisition of Celgene Corp., where he adeptly led research efforts in immunology and inflammation, showcasing his versatility and commitment to medical science.

A Robust Background in Medicine and Research

Before assuming his current role, Dr. Plenge held the position of Vice President and Head of Translational Medicine at Merck & Co., further solidifying his impressive curriculum vitae. He began his career in the hallowed halls of Harvard Medical School, where he served as an Assistant Professor of Medicine, and was an Associate Member of the Broad Institute, playing a vital role in advancing genomic research.

BioMarin's President and CEO, Alexander Hardy, lauded Dr. Plenge's appointment, emphasizing the important scientific perspective he will contribute. “Robert has spent his career at the leading edge of human genetics and drug discovery,” stated Hardy. This insight will be crucial as BioMarin continues to expand its pipeline for treatments aimed at genetic disorders. Hardy also noted Dr. Plenge's significant pharmaceutical industry experience, which he believes will be tremendously valuable as the company strives to innovate and enhance its product offerings.

The Future of Rare Disease Treatment

In a statement reflecting on BioMarin's past achievements, Dr. Plenge expressed his admiration for the company’s innovative approach over the past three decades, leading to the development of six first-in-disease therapies. “This is an impressive track record of scientific excellence,” he remarked. His excitement for joining the team signals a shared vision for future advancements, particularly in ensuring that more patients worldwide benefit from groundbreaking treatments.

BioMarin, established in 1997 and headquartered in San Rafael, California, has built a reputation as a leading biotech firm dedicated to addressing the needs of patients suffering from rare genetic diseases. The organization prides itself on its remarkable record of innovation with nine commercial treatments available and a robust clinical and preclinical pipeline.

Looking Ahead

As Dr. Plenge steps into his new role, his vision aligns with BioMarin's mission to unleash the potential of genetic science in the development of transformative medicines. The combination of Dr. Plenge’s extensive research background and BioMarin’s proven record positions the company well for continued success in developing therapies that profoundly impact the lives of patients living with rare diseases. The future looks bright as BioMarin embarks on this new chapter in its storied history, bolstering its commitment to medical advancements and patient care.

To learn more about BioMarin and their dedication to rare diseases, visit www.biomarin.com.